Kymera Therapeutics (KYMR) Retained Earnings (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Retained Earnings data on file, last reported at -$1.1 billion in Q1 2026.

• On a quarterly basis, Retained Earnings fell 38.38% year-over-year to -$1.1 billion in Q1 2026; TTM through Mar 2026 was -$1.1 billion, a 38.38% decrease from a year earlier, with the FY2025 full-year figure at $1.8 million, up 100.24% from the prior year.
• Retained Earnings for Q1 2026 stood at -$1.1 billion, down from $1.8 million in the prior quarter.
• Over the last five years, Retained Earnings for KYMR reached as high as $1.8 million in Q4 2025 and fell as low as -$1.1 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$424.6 million across 5 years, with a median of -$383.8 million in 2022.
• Across the five-year window, Retained Earnings slumped 58050.0% in 2022 and jumped 113.29% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$383.8 million in 2022, then slumped by 38.29% to -$530.8 million in 2023, then sank by 42.18% to -$754.6 million in 2024, then soared by 100.24% to $1.8 million in 2025, then slumped by 63155.56% to -$1.1 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$1.1 billion in Q1 2026, $1.8 million in Q4 2025, and -$979.0 million in Q3 2025.